S-Equol: a novel therapeutic for HIV-1-associated gastrointestinal dysbiosis
Mason T. Rodriguez, Sarah J. Olmstead, Kristen A. McLaurin, Charles F. Mactutus, Rosemarie M. Booze · 2025
Read S-Equol: a novel therapeutic for HIV-1-associated gastrointestinal dysbiosis by Mason T. Rodriguez, Sarah J. Olmstead, Kristen A. McLaurin, Charles F. Mactutus, Rosemarie M. Booze (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12755389.txt.
Description
Mason Rodriguez and co-authors test a soy compound against gut imbalance in an HIV rat model in a 2025 study. HIV infection leaves the gut microbiome disturbed even on good drug therapy, and gut brain links tie that disturbance to thinking problems. The compound, S-equol, was tried as a gut tuning treatment in virus carrying rats and normal controls.
Animals worked for cocaine on a hard progressive schedule while their gut microbes were profiled. Gut communities differed by strain at broad and genus levels whatever the treatment. The compound shifted microbes and interacted with strain, and one genus tracked lever pressing for the drug, hinting at a motivation link. The authors frame the gut as a treatment target.
Catalog record
| CREATOR | Mason T. Rodriguez, Sarah J. Olmstead, Kristen A. McLaurin, Charles F. Mactutus, Rosemarie M. Booze |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |